NASDAQ:XTLB - X T L Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding X T L Biopharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.31 -0.05 (-3.67 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$1.31Now: $1.31▼$1.3650-Day Range$1.21MA: $1.30▼$1.4252-Week Range$1.17Now: $1.31▼$2.75Volume2,263 shsAverage Volume15,894 shsMarket Capitalization$6.74 millionP/E Ratio8.75Dividend YieldN/ABeta0.95 ProfileAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XTLB Previous Symbol CUSIPN/A CIK1023549 Webhttp://www.xtlbio.com/ Phone972-9955-7080Debt Debt-to-Equity RatioN/A Current Ratio39.53 Quick RatioN/APrice-To-Earnings Trailing P/E Ratio8.75 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.56 per share Price / Cash Flow2.34 Book Value$1.62 per share Price / Book0.81Profitability EPS (Most Recent Fiscal Year)N/A Net Income$2.99 million Net MarginsN/A Return on Equity8.54% Return on Assets8.34%Miscellaneous EmployeesN/A Outstanding Shares5,140,000Market Cap$6.74 million Next Earnings Date3/9/2020 (Estimated) OptionableNot Optionable Receive XTLB News and Ratings via Email Sign-up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:XTLB Rates by TradingView X T L Biopharmaceuticals (NASDAQ:XTLB) Frequently Asked Questions What is X T L Biopharmaceuticals' stock symbol? X T L Biopharmaceuticals trades on the NASDAQ under the ticker symbol "XTLB." When did X T L Biopharmaceuticals' stock split? How did X T L Biopharmaceuticals' stock split work? Shares of X T L Biopharmaceuticals reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of X T L Biopharmaceuticals stock prior to the reverse split would have 20 shares after the split. How were X T L Biopharmaceuticals' earnings last quarter? X T L Biopharmaceuticals Ltd (NASDAQ:XTLB) announced its earnings results on Wednesday, November, 27th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter. View X T L Biopharmaceuticals' Earnings History. When is X T L Biopharmaceuticals' next earnings date? X T L Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for X T L Biopharmaceuticals. Has X T L Biopharmaceuticals been receiving favorable news coverage? Headlines about XTLB stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. X T L Biopharmaceuticals earned a coverage optimism score of -3.7 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days. View News Stories for X T L Biopharmaceuticals. Who are some of X T L Biopharmaceuticals' key competitors? Some companies that are related to X T L Biopharmaceuticals include Bellerophon Therapeutics (BLPH), Genprex (GNPX), Aerpio Pharmaceuticals (ARPO), Sernova (SEOVF), Kazia Therapeutics (KZIA), Regulus Therapeutics (RGLS), Provectus Biopharmaceuticals (PVCT), Zosano Pharma (ZSAN), AEterna Zentaris (AEZS), Sophiris Bio (SPHS), Guardion Health Sciences (GHSI), Cellectar Biosciences (CLRB), Teligent (TLGT), China SXT Pharmaceuticals (SXTC) and Ceapro (CRPOF). What other stocks do shareholders of X T L Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X T L Biopharmaceuticals investors own include Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), Akari Therapeutics (AKTX), Exelixis (EXEL), Neurocrine Biosciences (NBIX), TRACON Pharmaceuticals (TCON), T2 Biosystems (TTOO), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD) and Vascular Biogenics (VBLT). Who are X T L Biopharmaceuticals' key executives? X T L Biopharmaceuticals' management team includes the folowing people: Mr. Joshua Levine, Chief Exec. Officer (Age 53)Mr. Itay Weinstein, Chief Financial Officer (Age 48)Mr. Ronen Kantor Adv, Company Sec. How do I buy shares of X T L Biopharmaceuticals? Shares of XTLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is X T L Biopharmaceuticals' stock price today? One share of XTLB stock can currently be purchased for approximately $1.31. How big of a company is X T L Biopharmaceuticals? X T L Biopharmaceuticals has a market capitalization of $6.74 million. View Additional Information About X T L Biopharmaceuticals. What is X T L Biopharmaceuticals' official website? The official website for X T L Biopharmaceuticals is http://www.xtlbio.com/. How can I contact X T L Biopharmaceuticals? X T L Biopharmaceuticals' mailing address is 5 HACHAROSHET ST., RAANANA L3, 43656. The biopharmaceutical company can be reached via phone at 972-9955-7080 or via email at [email protected] MarketBeat Community Rating for X T L Biopharmaceuticals (NASDAQ XTLB)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 77 (Vote Outperform)Underperform Votes: 60 (Vote Underperform)Total Votes: 137MarketBeat's community ratings are surveys of what our community members think about X T L Biopharmaceuticals and other stocks. Vote "Outperform" if you believe XTLB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XTLB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/25/2020 by MarketBeat.com StaffFeatured Article: What is Liquidity?
